Fig. 2From: Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in GermanyCost-efficiency frontier. BR: Background Regimen; QALY: Quality-Adjusted Life YearBack to article page